NCT06905210View on ClinicalTrials.gov

Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

526

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions
Acne VulgarisAcne Vulgaris on the Face
Interventions
DRUG

Placebo of the experimental drug

Subjects randomized to this group will receive one (01) placebo of the experimental drug everyday for 28 weeks.

DRUG

Experimental drug

Subjects randomized to this group will receive one (01) experimental drug everyday for 28 weeks.

Trial Locations (1)

06696-000

Eurofarma Laboratórios S.A, Itapevi

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY